Publications by authors named "C Benavente"
Article Synopsis
- * Thirteen studies were analyzed, and results indicated only a small advantage for RTH over RTN in improving strength as measured by the 1-repetition maximum (1RM) test, with a significant difference in specific training methods.
- * It was found that non-full-body routines with 9 or more weekly sets of multi-joint exercises performed to non-failure may enhance strength development in hypoxic conditions, suggesting a slight benefit for targeted resistance training approaches.
Article Synopsis
- Hypobaric hypoxia (HH) affects oxygen supply and increases energy demands during exercise, which can influence body composition and metabolic responses.
- A study involving 20 trained men showed that 8 weeks of resistance training in HH led to changes in subcutaneous adipose tissue (SAT) thickness and serum levels of metabolic cytokines, including reductions in IL-6 and irisin.
- The training in HH also boosted IL-15 levels, which correlated with significant reductions in SAT, indicating that exercising under HH may enhance body composition by altering cytokine profiles.
Ubiquitin-like with PHD and RING finger domains 1 (UHRF1) is an essential protein involved in the maintenance of repressive epigenetic marks, ensuring epigenetic stability and fidelity. As an epigenetic regulator, UHRF1 comprises several functional domains (UBL, TTD, PHD, SRA, RING) that are collectively responsible for processes like DNA methylation, histone modification, and DNA repair. UHRF1 is a downstream effector of the RB/E2F pathway, which is nearly universally deregulated in cancer.
View Article and Find Full Text PDFThis study investigated the effect of a resistance training (R) period at terrestrial (HH) and normobaric hypoxia (NH) on both muscle hypertrophy and maximal strength development with respect to the same training in normoxia (N). Thirty-three strength-trained males were assigned to N (FiO = 20.9%), HH (2,320 m asl) or NH (FiO = 15.
View Article and Find Full Text PDFSmall cell lung cancer (SCLC) is a deadly neuroendocrine malignancy, notorious for its rapid tumor growth, early metastasis, and relatively "cold" immune environment. Only standard chemotherapies and a few immune checkpoint inhibitors have been approved for SCLC treatment, revealing an urgent need for novel therapeutic approaches. Moreover, SCLC has been recently recognized as a malignancy with high intratumoral and intertumoral heterogeneity, which explains the modest response rate in some patients and the early relapse.
View Article and Find Full Text PDF